Citations

Clear

1011 citation(s) found for "Barry, WT".

Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure
Borlaug, Barry A. , Blair, John, Bergmann, Martin W., Bugger, Heiko, Burkhoff, Daniel , Bruch, Leonhard , Celermajer, David S. , Claggett, Brian , Cleland, John G.F., Cutlip, Donald E. , Dauber, Ira, Eicher, Jean-Christophe , Gao, Qi, Gorter, Thomas M. , Gustafsson, Finn , Heyden, Jan van der, Hasenfuß, Gerd, Hummel, Scott L. , Komtebedde, Jan, Mazurek, Jeremy A., McKenzie, Scott , Mehta, Shamir R. , Petrie, Mark C. , Post, Marco C., Nair, Ajith, Rieth, Andreas , Silvestry, Frank E., Solomon, Scott D. , Trochu, Jean‐Noël , Veldhuisen, Dirk J. Van, Westenfeld, Ralf, Leon, Martin B., Investigators, on behalf of the REDUCE LAP-HF-II, Bugger, Heiko , Nair, Ajith , Burkhoff, Daniel , Hayward, Chris , Hummel, Scott L , Kaye, David M , Massaro, Joseph M. , McKenzie, Scott , Mehta, Shamir R , Petrie, Mark C , Rieth, Andreas , Solomon, Scott David , Trochu, Jean-Noël , Shah, Sanjiv J , Borlaug, Barry A , Nair, Ajith P , Celermajer, David , Gustafsson, Finn , Blair, John, Bergmann, Martin W., Bruch, Leonhard , Claggett, Brian L , Cleland, John G.F., Cutlip, Donald E. , Dauber, Ira, Eicher, Jean-Christophe , Gao, Qi, Gorter, Thomas M. , Heyden, Jan van der, Hasenfuß, Gerd, Komtebedde, Jan, Mazurek, Jeremy A., Post, Marco C., Nair, Ajith, Silvestry, Frank E., Veldhuisen, Dirk J. Van, Westenfeld, Ralf, Leon, Martin B., Investigators, on behalf of the REDUCE LAP-HF-II

Mayo Clinic

Circulation | March 31, 2022 | Volume: 145 | Issue: 21 | Pages: 1592-1604

10.1161/circulationaha.122.059486 | PMID 35354306 Get It

Background: In REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure), implantation of an atrial shunt device did not provide overall clinical benefit for patients with heart failure with preserved or mildly reduced ejection fraction. However, prespecified analyses identified differences in response in subgroups defined by pulmonary artery systolic pressure during submaximal exercise, right atrial volume, and sex. Shunt implantation reduces left atrial pressures but increases pulmonary blood flow, which may be poorly tolerated in patients with pulmonary vascular disease (PVD). On the basis of these results, we hypothesized that patients with latent PVD, defined as elevated pulmonary vascular resistance during exercise, might be harmed by shunt implantation, and conversely that patients without PVD might benefit. Methods: REDUCE LAP-HF II enrolled 626 patients with heart failure, ejection fraction ≥40%, exercise pulmonary capillary wedge pressure ≥25 mm Hg, and resting pulmonary vascular resistance <3.5 Wood units who were randomized 1:1 to atrial shunt device or sham control. The primary outcome—a hierarchical composite of cardiovascular death, nonfatal ischemic stroke, recurrent HF events, and change in health status—was analyzed using the win ratio. Latent PVD was defined as pulmonary vascular resistance ≥1.74 Wood units (highest tertile) at peak exercise, measured before randomization. Results: Compared with patients without PVD (n=382), those with latent PVD (n=188) were older, had more atrial fibrillation and right heart dysfunction, and were more likely to have elevated left atrial pressure at rest. Shunt treatment was associated with worse outcomes in patients with PVD (win ratio, 0.60 [95% CI, 0.42, 0.86]; P =0.005) and signal of clinical benefit in patients without PVD (win ratio, 1.31 [95% CI, 1.02, 1.68]; P =0.038). Patients with larger right atrial volumes and men had worse outcomes with the device and both groups were more likely to have pacemakers, heart failure with mildly reduced ejection fraction, and increased left atrial volume. For patients without latent PVD or pacemaker (n=313; 50% of randomized patients), shunt treatment resulted in more robust signal of clinical benefit (win ratio, 1.51 [95% CI, 1.14, 2.00]; P =0.004). Conclusions: In patients with heart failure with preserved or mildly reduced ejection fraction, the presence of latent PVD uncovered by invasive hemodynamic exercise testing identifies patients who may worsen with atrial shunt therapy, whereas those without latent PVD may benefit.
How do I implement an outpatient program for the administration of convalescent plasma for COVID‐19?
Bloch, Evan M. , Tobian, Aaron A.R. , Gniadek, Thomas J. , Cachay, Edward R. , Kafka, Kimberly, Marshall, Christi E., Heath, Sonya L. , Forthal, Donald N. , Fukuta, Yuriko , Huamán, Moisés A. , Ziman, Alyssa , Adamski, Jill , Gerber, Jonathan M. , Cruser, Daniel, Patel, Bela , Metcalf, Ryan A. , Reisler, Ronald B. , Yarava, Anusha , Lane, Karen , McBee, Nichol , Gawad, Amy L., Abinante, Matthew, Broderick, Patrick , Sullivan, David , Ziman, Alyssa , Adamksi, Jill , Raval, Jay S , Metcalf, Ryan A , Tobian, Aaron A R , Huaman, Moises A , Sullivan, David J , Shoham, Shmuel , Hanley, Daniel F. , Meisenberg, Barry R. , Shenoy, Aarthi , Paxton, James H , Levine, Adam C , Kassaye, Seble , Mosnaim, Giselle S , Anjan, Shweta , Raval, Jay S. , Zand, Martin S. , Broderick, Patrick B., Casadevall, Arturo , Gebo, Kelly A

Mayo Clinic

Transfusion | March 30, 2022 | Volume: 62 | Issue: 5 | Pages: 933-941

10.1111/trf.16871 | PMID 35352362 Get It

AbstractConvalescent plasma, collected from donors who have recovered from a pathogen of interest, has been used to treat infectious diseases, particularly in times of outbreak, when alternative therapies were unavailable. The COVID‐19 pandemic revived interest in the use of convalescent plasma. Large observational studies and clinical trials that were executed during the pandemic provided insight into how to use convalescent plasma, whereby high levels of antibodies against the pathogen of interest and administration early within the time course of the disease are critical for optimal therapeutic effect. Several studies have shown outpatient administration of COVID‐19 convalescent plasma (CCP) to be both safe and effective, preventing clinical progression in patients when administered within the first week of COVID‐19. The United States Food and Drug Administration expanded its emergency use authorization (EUA) to allow for the administration of CCP in an outpatient setting in December 2021, at least for immunocompromised patients or those on immunosuppressive therapy. Outpatient transfusion of CCP and infusion of monoclonal antibody therapies for a highly transmissible infectious disease introduces nuanced challenges related to infection prevention. Drawing on our experiences with the clinical and research use of CCP, we describe the logistical considerations and workflow spanning procurement of qualified products, infrastructure, staffing, transfusion, and associated management of adverse events. The purpose of this description is to facilitate the efforts of others intent on establishing outpatient transfusion programs for CCP and other antibody‐based therapies.
Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications
Omote, Kazunori , Sorimachi, Hidemi, Obokata, Masaru , Reddy, Yogesh N.V. , Verbrugge, Frederik H. , Redfield, Margaret M. , Borlaug, Barry A. , Omar, Massar , Borlaug, Barry A , Nishimura, Rick , Obokata, Masaru , Verbrugge, Frederik H , Omar, Massar , DuBrock, Hilary M.

Mayo Clinic

European Heart Journal | March 29, 2022 | Volume: 43 | Issue: 36 | Pages: 3417-3431

10.1093/eurheartj/ehac184 | PMID 35796488 Get It

Abstract Aims Pulmonary hypertension (PH) and pulmonary vascular disease (PVD) are common and associated with adverse outcomes in left heart disease (LHD). This study sought to characterize the pathophysiology of PVD across the spectrum of PH in LHD. Methods and results Patients with PH-LHD [mean pulmonary artery (PA) pressure &gt;20 mmHg and PA wedge pressure (PAWP) ≥15 mmHg] and controls free of PH or LHD underwent invasive haemodynamic exercise testing with simultaneous echocardiography, expired air and blood gas analysis, and lung ultrasound in a prospective study. Patients with PH-LHD were divided into isolated post-capillary PH (IpcPH) and PVD [combined post- and pre-capillary PH (CpcPH)] based upon pulmonary vascular resistance (PVR &lt;3.0 or ≥3.0 WU). As compared with controls (n = 69) and IpcPH-LHD (n = 55), participants with CpcPH-LHD (n = 40) displayed poorer left atrial function and more severe right ventricular (RV) dysfunction at rest. With exercise, patients with CpcPH-LHD displayed similar PAWP to IpcPH-LHD, but more severe RV–PA uncoupling, greater ventricular interaction, and more severe impairments in cardiac output, O2 delivery, and peak O2 consumption. Despite higher PVR, participants with CpcPH developed more severe lung congestion compared with both IpcPH-LHD and controls, which was associated lower arterial O2 tension, reduced alveolar ventilation, decreased pulmonary O2 diffusion, and greater ventilation-perfusion mismatch. Conclusions Pulmonary vascular disease in LHD is associated with a distinct pathophysiologic signature marked by greater exercise-induced lung congestion, arterial hypoxaemia, RV–PA uncoupling, ventricular interdependence, and impairment in O2 delivery, impairing aerobic capacity. Further study is required to identify novel treatments targeting the pulmonary vasculature in PH-LHD.
A framework for examining patient attitudes regarding applications of artificial intelligence in healthcare
Richardson, Jordan , Smith, Cambray , Barry, Barbara , Sharp, Richard R. , Richardson, Jordan P , Curtis, Susan , Pacyna, Joel, Zhu, Xuan , Barry, Barbara , Sharp, Richard R , Pacyna, Joel E.

Mayo Clinic

DIGITAL HEALTH | March 25, 2022 | Volume: 8 | Issue: No issue available | Pages: 205520762210890

10.1177/20552076221089084 | PMID 35355806 Get It

Background While use of artificial intelligence (AI) in healthcare is increasing, little is known about how patients view healthcare AI. Characterizing patient attitudes and beliefs about healthcare AI and the factors that lead to these attitudes can help ensure patient values are in close alignment with the implementation of these new technologies. Methods We conducted 15 focus groups with adult patients who had a recent primary care visit at a large academic health center. Using modified grounded theory, focus-group data was analyzed for themes related to the formation of attitudes and beliefs about healthcare AI. Results When evaluating AI in healthcare, we found that patients draw on a variety of factors to contextualize these new technologies including previous experiences of illness, interactions with health systems and established health technologies, comfort with other information technology, and other personal experiences. We found that these experiences informed normative and cultural beliefs about the values and goals of healthcare technologies that patients applied when engaging with AI. The results of this study form the basis for a theoretical framework for understanding patient orientation to applications of AI in healthcare, highlighting a number of specific social, health, and technological experiences that will likely shape patient opinions about future healthcare AI applications. Conclusions Understanding the basis of patient attitudes and beliefs about healthcare AI is a crucial first step in effective patient engagement and education. The theoretical framework we present provides a foundation for future studies examining patient opinions about applications of AI in healthcare.
Collaboration and Shared Decision-Making Between Patients and Clinicians in Preventive Health Care Decisions and US Preventive Services Task Force Recommendations
Force, US Preventive Services Task, Davidson, Karina W. , Mangione, Carol M. , Nicholson, Wanda K. , Cabana, Michael D. , Caughey, Aaron B. , Davis, Esa M. , Donahue, Katrina E , Kubik, Martha , Li, Li , Ogedegbe, Gbenga, Silverstein, Michael, Stevermer, James , Tseng, Chien‐Wen , Wong, John B. , Doubeni, Chyke A. , Davidson, Karina , Force, US Preventive Services Task, Barry, Michael J. , Pbert, Lori A.

Mayo Clinic

JAMA | March 22, 2022 | Volume: 327 | Issue: 12 | Pages: 1171

10.1001/jama.2022.3267 | PMID 35315879 Get It

Social Media and Professional Development for Oncology Professionals
Chidharla, Anusha , Attai, Deanna J. , Drake, Emily K. , Londen, G. J. van , Subbiah, Ishwaria M. , Henry, Elizabeth , Murphy, Martina, Barry, Maura , Manochakian, Rami , Leyfman, Yan , Utengen, Audun , Attai, Deanna J , Drake, Emily K , van Londen, G J , Subbiah, Ishwaria M , Henry, Elizabeth , Barry, Maura M , Manochakian, Rami , Moerdler, Scott , Loeb, Stacy , Graff, Stephanie L , Leyfman, Yan , Thompson, Michael A , Markham, Merry J , Utengen, Audun , Loeb, Stacy , Graff, Stephanie L. , Thompson, Michael A, Markham, Merry Jennifer

Mayo Clinic

JCO Oncology Practice | March 21, 2022 | Volume: 18 | Issue: 8 | Pages: 566-571

10.1200/op.21.00761 | PMID 35312343 Get It

The use of social media continues to increase in health care and academia. Health care practice, particularly the oncologic field, is constantly changing because of new knowledge, evidence-based research, clinical trials, and government policies. Therefore, oncology trainees and professionals continue to strive to stay up-to-date with practice guidelines, research, and skills. Although social media as an educational and professional development tool is no longer completely new to medicine and has been embraced, it is still under-researched in terms of various outcomes. Social media plays several key roles in professional development and academic advancement. We reviewed the literature to evaluate how social media can be used for professional development and academic promotion of oncology professionals.
The Value of Passive Leg Raise During Right Heart Catheterization in Diagnosing Heart Failure With Preserved Ejection Fraction
Bovenkamp, Arno A. van de , Wijkstra, Niels, Oosterveer, Frank, Noordegraaf, Anton Vonk , Bogaard, Harm Jan , Rossum, Albert C. van , Man, Frances S. de , Borlaug, Barry A. , Handoko, M. Louis , van de Bovenkamp, Arno A , Vonk Noordegraaf, Anton , van Rossum, Albert C , de Man, Frances S , Borlaug, Barry A

Mayo Clinic

Circulation: Heart Failure | March 21, 2022 | Volume: 15 | Issue: 4 | Pages: No page available

10.1161/circheartfailure.121.008935 | PMID 35311526 Get It

Background: Because of limited accuracy of noninvasive tests, diastolic stress testing plays an important role in the diagnostic work-up of patients with heart failure with preserved ejection fraction (HFpEF). Exercise right heart catheterization is considered the gold standard and indicated when HFpEF is suspected but left ventricular filling pressures at rest are normal. However, performing exercise during right heart catheterization is not universally available. Here, we examined whether pulmonary capillary wedge pressure (PCWP) during a passive leg raise (PLR) could be used as simple and accurate method to diagnose or rule out occult-HFpEF. Methods: In our tertiary center for pulmonary hypertension and HFpEF, all patients who received a diagnostic right heart catheterization with PCWP-measurements at rest, PLR, and exercise were evaluated (2014–2020). The diagnostic value of PCWP PLR was compared with the gold standard (PCWP EXERCISE ). Cut-offs derived from our cohort were subsequently validated in an external cohort (N=74). Results: Thirty-nine non-HFpEF, 33 occult-HFpEF, and 37 manifest-HFpEF patients were included (N=109). In patients with normal PCWP REST (<15 mmHg), PCWP PLR significantly improved diagnostic accuracy compared with PCWP REST (AUC=0.82 versus 0.69, P =0.03). PCWP PLR ≥19 mmHg (24% of cases) had a specificity of 100% for diagnosing occult-HFpEF, irrespective of diuretic use. PCWP PLR ≥11 mmHg had a 100% sensitivity and negative predictive value for diagnosing occult-HFpEF. Both cut-offs retained a 100% specificity and 100% sensitivity in the external cohort. Absolute change in PCWP PLR or V-wave derived parameters had no incremental value in diagnosing occult-HFpEF. Conclusions: PCWP PLR is a simple and powerful tool that can help to diagnose or rule out occult-HFpEF.
Abstract 1: Did Carotid Stenting and Endarterectomy Outcomes Change Over Time in the Carotid Revascularization Endarterectomy versus Stenting Trial?
Roubin, Gary S., Hopkins, L. Nelson , Moore, Wesley S. , Gray, William A. , Katzen, Barry T. , Chakhtoura, Elie, Morrish, William, Ferguson, R. , Shawl, Fayaz A., Harrigan, Mark R. , Voeks, Jenifer H. , Lal, Brajesh K. , Brott, Thomas G. , Howard, George , Rosenfield, Kenneth , Hye, Robert J. , Meschia, James F.

Mayo Clinic

Stroke | March 20, 2022 | Volume: 43 | Issue: suppl_1 | Pages: No page available

10.1161/str.43.suppl_1.a1 Get It

Background The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) enrolled 2502 patients between December of 2000 and mid-July of 2008. We analyzed temporal changes in outcomes for both CEA and CAS over the course of this study. Methods Enrollment was divided into 3 consecutive epochs (5 years, 14 months, and 16 months), each with approximately 834 patients ( Table ). Rates for the primary outcome of death, stroke, and myocardial infarction (DSMI) and for death and stroke (DS) during the periprocedural period were calculated. Poisson regression was used to adjust rates for age, sex, dyslipidemia, and symptomatic status, all of which were found to influence outcomes. Results For CAS, there was a 26% decline in DSMI (6.2% → 4.6%) and a 35% decline in DS (5.5% → 3.6%). For both composite endpoints in CEA there was no consistent pattern ( Table ). As CREST progressed, it enrolled younger patients, more men, patients more likely to be dyslipidemic and enrolled more asymptomatic patients (all p < 0.05). Adjustment for these changes mediated the improvement in event rates for the CAS patients, and had no consistent effect on CEA event rates ( Table ). Conclusion Periprocedural safety for CAS improved over time in CREST. Changes were inconsistent for CEA. Improvements for CAS in part appear to reflect changes in patient selection related to age, sex, and risk factors, as adjustment for those variables attenuated the decline in rates. Linking rates to operator experience was not feasible because of the large number of new interventionalists and surgeons entering CREST over time.
Abstract 11454: Unsupervised Machine Learning Identified High-Risk Phenotype in Heart Failure Patients with Syncope
Sriramoju, Anil , Tagle-Cornell, Maria Cecilia , Koepke, Laura, KoKo, Nway, Fatunde, Olubadewa A. , Shanbhag, Anusha , Barry, Timothy , Wu, Hanlun, Shen, Win K., Chao, Chieh‐Ju , Rattanawong, Pattara , Wu, Han-Lun

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.11454 Get It

Introduction: Syncope was reported to be associated with sudden cardiac death in heart failure patients regardless of the etiology of syncope. We attempted to use unsupervised machine learning to identify the prognostically distinct phenotypes in a large population of heart failure patients presenting with syncope. Hypothesis: Unsupervised machine learning can identify prognostically distinct phenotypes in a large population of heart failure patients presenting with syncope. Methods: Patients with a diagnosis of systolic or diastolic heart failure and syncope at Mayo Clinic sites were identified for baseline and follow-up data. Variables with ≥ 20% missing data were excluded; a total of 57 variables were used for k-means clustering analysis. Patients were grouped according to 4 distinct k-means determined clusters for statistical analysis. Results: A total of 3,557 patients with proper follow-up and echocardiography data were included in the final analysis. The median follow-up duration was 36.3 months, and 2908 (81.7%) patients died. Cluster 2 (n= 680) was identified as the cluster with the highest mortality (92%), which contained patients with high proportions of cardiovascular comorbidities, especially chronic kidney disease. The Kaplan-Meier survival curves are shown in Figure 1. In multivariate Cox regression analysis, the presence of CKD independently predicts mortality (HR 1.62, 95%CI 1.50-1.76, p <0.0001) after adjusting for age and sex. Conclusions: Unsupervised machine learning identified patients with CKD, CAD and DM are high-risk phenotypes in heart failure patients with syncope, and can be used to guide future studies in this highly heterogeneous, unexplored population.
Abstract 11432: The Impact of Regional Adipose Tissue Deposition on Physical Activity in Heart Failure with Preserved Ejection Fraction
Koepp, Katlyn E. , Quicksall, Zachary , Sorimachi, Hidemi, Egbe, Alexander C. , Bruhn, Eric J., Olson, Thomas P. , Reddy, Yogesh N.V. , Obokata, Masaru , Verbrugge, Frederik H. , Carter, Rickey E. , Borlaug, Barry A.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.11432 Get It

Introduction: Obesity is common in heart failure with preserved ejection fraction (HFpEF) and is directly linked with lower levels of physical activity (PA). Visceral adiposity (VAT) is more common in HFpEF than controls and may play a role in its pathogenesis, characterized by impaired exercise capacity (peak VO 2 ). The direct relationship between VAT and PA in HFpEF is unknown. Hypothesis: Compared to controls, HFpEF patients will have excess regional adiposity (VAT, subcutaneous (SAT), and intramuscular (IMAT)), and these fat depots will be associated with lower levels of chronic physical activity. Methods: HFpEF patients (n=51; age 70±9) and non-HFpEF controls (n=49; age 65±5) prospectively underwent body composition measurement by dual-energy x-ray absorptiometry and magnetic resonance imaging. Peak VO 2 was measured by standard cardiopulmonary exercise testing. PA was monitored continuously via accelerometry over two weeks. Data were binned in arbitrary accelerometry units, averaged and stored in 30-second epochs (counts per epoch, CPE). Models were adjusted for age, sex, and ideal body weight. Results: HFpEF were less active overall (3.15±0.80 vs 3.59±0.73 CPE), had less moderate intensity PA (10.13±0.04 vs 10.15±0.03 CPE), and less morning (3.83±1.15 vs 4.24±1.09 CPE) and afternoon (3.84± 1.20 vs 4.53± 0.97 CPE) (p<0.05 for all) PA. Patients with HFpEF spent a greater proportion of time sedentary (0.71±0.08 vs 0.67±0.08 CPE) and less time in moderate (0.04±0.03 vs 0.06±0.03 CPE) and vigorous (0.02±0.01 vs 0.03±0.03 CPE) PA (p<0.01 for all). Chronic PA was significantly associated with regional fat depots (VAT β= -0.003, 95% CI: -0.004-0.001; SAT β= -0.003, 95%CI: -0.004-0.001; IMAT β=-0.02, 95% CI: -0.04—0.01) as a combined cohort (p<0.01 for all). Muscle quality (β=0.28, 95%CI: 0.15-0.40), peak VO 2 (β=0.08, 95% CI: 0.03-0.13), and peak watts (β=0.01, 95% CI: -0.004-0.02) were associated with PA in HFpEF only (p≤0.01 for all). Conclusions: The amount and pattern of PA differs between HFpEF and controls, as do relationships between regional fat depots and PA, and the relationship of PA and peak VO 2 . Further investigation is needed to better understand the temporality and mechanisms related to the pathophysiology and severity of HFpEF.